Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
- Conditions
- Myeloid Leukemia
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT00126893
- Locations
- 🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
- Conditions
- Coronary Restenosis
- Interventions
- Drug: Nanoparticle Paclitaxel
- First Posted Date
- 2005-07-29
- Last Posted Date
- 2012-04-02
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 112
- Registration Number
- NCT00124943
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy
- First Posted Date
- 2005-07-15
- Last Posted Date
- 2009-09-23
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 181
- Registration Number
- NCT00120120
- Locations
- 🇺🇸
Loma Linda Institution, Loma Linda, California, United States
🇺🇸Washington University Pain Mgmt Ctr, St. Louis, Missouri, United States
🇺🇸Texas Tech Medical Center Department of Anesthesiology, Lubbock, Texas, United States
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1
- Conditions
- Complex Regional Pain Syndrome, Type I
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 184
- Registration Number
- NCT00109772
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Washington University Pain Mgmt Ctr, St. Louis, Missouri, United States
🇺🇸Lehigh Valley Hospital, Allentown, Pennsylvania, United States
Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2007-07-20
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT00107094
- Locations
- 🇺🇸
Abraxis BioScience Inc., Durham, North Carolina, United States
A Research Study for Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Carcinoma, Renal CellNeoplasm Metastasis
- Interventions
- Drug: FK228 (romidepsin)
- First Posted Date
- 2005-03-29
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 30
- Registration Number
- NCT00106613
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
A Research Study for Patients With Prostate Cancer
- First Posted Date
- 2005-03-25
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 35
- Registration Number
- NCT00106418
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
- Conditions
- Cutaneous T-cell Lymphoma
- First Posted Date
- 2005-03-25
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 102
- Registration Number
- NCT00106431
- Locations
- 🇺🇸
UCLA Jonsson Cancer Center, Los Angeles, California, United States
🇺🇸Stanford Comprehensive Cancer Center, Stanford, California, United States
🇺🇸University of Pennsylvania Abrahamson Cancer Center, Philadelphia, Pennsylvania, United States
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
- Conditions
- Carcinoma, Renal CellProstatic Neoplasms
- Interventions
- Drug: FK228 (romidepsin)
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 2
- Registration Number
- NCT00106301
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
- First Posted Date
- 2005-02-01
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 151
- Registration Number
- NCT00102687
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Research Department, Bakersfield, California, United States
🇺🇸Great Lakes Cancer Institute Breslin Cancer Center, Lansing, Michigan, United States
🇺🇸Greater Dayton Cancer Center, Kettering, Ohio, United States